Xcout IntelProbiodrug competitors & alternatives
The 12 closest competitors and alternatives to Probiodrug among biotechnology companies — ranked by similarity to what Probiodrug actually does, not by market-cap band.
Subscribe to see Probiodrug’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Probiodrug
Probiodrug AG is a biopharmaceutical company headquartered in Halle, Germany, that aims to become a leading enterprise in its field and has previously held an initial public offering on Euronext Amsterdam. The company's focus includes addressing conditions such as Alzheimer's disease through specialized therapeutic development.
Probiodrug at a glance
Probiodrug is a biotechnology company headquartered in Germany, founded in 1997. It has raised at least $81.3M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $27.3M in January 2012.
Probiodrug funding rounds
At least $81.3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $27.3M | 1 named | |
| Series B | $54M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Probiodrug competitors
Ranked by semantic similarity — how close each company is to Probiodrug by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
EXCIVA GmbH is a privately held biotechnology company established in 2016 in Heidelberg, Germany, focused on developing clinical-stage therapeutics to improve quality of life and treat Alzheimer's disease.
Biotech
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Similar biotechnology company
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Biotech
BioArctic AB (publ) is an innovative Swedish research-based biopharma company headquartered in Stockholm, Sweden. Incorporated in 2000, it focuses on developing disease-modifying treatments for neurodegenerative diseases. The company is publicly traded and committed to corporate governance.
Similar biotechnology company
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Biotech
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Similar biotechnology company
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Similar biotechnology company
Ultimate Medicine AG is a Swiss preclinical biotechnology company headquartered in Zürich, focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias by targeting novel toxic metabolites.
Biotech
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Biotech
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Similar biotechnology company
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Similar biotechnology company
Syremis Therapeutics Ltd. is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, dedicated to developing novel drug pipeline medicines targeted at treating diseases of the nervous system and mental health disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Probiodrug and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Probiodrugand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →